Terns Pharmaceuticals faces market pressure following stock offering announcement
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing small-molecule product candidates for serious diseases such as oncology and obesity, has seen a significant decline in ... Read More
Ardent Health Partners’ $192m IPO breaks ground—What this means for the future of U.S. healthcare
Ardent Health Partners, Inc. (NYSE: ARDT), a prominent healthcare provider for midsize urban communities across the United States, has successfully closed its initial public offering ... Read More